Oncorus to Present at the Oppenheimer 32nd Annual Healthcare Conference

Rhea-AI Summary

Oncorus, a company specializing in viral immunotherapies, announced that CEO Theodore Ashburn will present at the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 4:40 p.m. ET. The presentation aims to showcase Oncorus' innovative approaches in cancer treatment, particularly their Herpes Simplex Virus (HSV) and selectively self-amplifying viral RNA (vRNA)/lipid nanoparticle platforms. A live webcast will be available on their website, with a replay accessible for 30 days post-event.

News Market Reaction – ONCR

-8.50%

-8.50% Session move

In the trading session that priced this news, ONCR declined 8.50%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will present at the Oppenheimer 32^nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 4:40 p.m. ET.

A live webcast of the presentation can be accessed by visiting the Investors & Media section of Oncorus’ website at https://investors.oncorus.com/. A replay of the presentation will be archived on Oncorus’ site for 30 days following the event.

About Oncorus

At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. We are advancing a portfolio of intratumorally (iTu) and intravenously (IV) administered viral immunotherapies for multiple indications with significant unmet need based on our Herpes Simplex Virus (HSV) Platform and selectively self-amplifying viral RNA (vRNA)/ lipid nanoparticle (LNP) Immunotherapy Platform.

Designed to deliver next-generation viral immunotherapy impact, our HSV Platform improves upon key characteristics of this therapeutic class to enhance systemic activity. Our lead HSV program, ONCR-177, is designed to be directly administered into a tumor, resulting in high local concentrations of the therapeutic agent and its five encoded transgenes, as well as low systemic exposure to the therapy, which could limit systemic toxicities. Our pioneering selectively self-amplifying vRNA Immunotherapy Platform involves a highly innovative, novel combination of RNA and oncolytic virus-based modalities designed to realize the potential of RNA medicines for cancer. Our lead IV-administered selectively self-amplifying vRNA Immunotherapy clinical candidates, ONCR-021 and ONCR-788, are both currently in IND-enabling studies.

Please visit www.oncorus.com to learn more.
           
Investor Contact:
Stern Investor Relations
Julie Seidel
Julie.seidel@sternir.com 

FAQ

When is Oncorus CEO presenting at the Oppenheimer Healthcare Conference?

Oncorus CEO Theodore Ashburn will present on March 15, 2022, at 4:40 p.m. ET.

How can I watch the Oncorus presentation at the Oppenheimer Conference?

You can watch the Oncorus presentation live via webcast on their Investors & Media website.

What is the focus of Oncorus' presentation at the conference?

The presentation will highlight Oncorus' advancements in viral immunotherapies for cancer treatment.

What are Oncorus' lead clinical candidates mentioned in the press release?

Oncorus' lead clinical candidates include ONCR-177, ONCR-021, and ONCR-788.

Where can I find more information about Oncorus?

For more information, you can visit Oncorus' official website at www.oncorus.com.